Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

<ul><li>Stryker Corporation had a decent result in the quarter and the company posted an increase in organic sales growth which was driven by double-digit growth from its Neuro-technology and MedSurg businesses.</li><li>Though the company’s implant businesses were challenged, the company’s capital products performed better than its MedSurg portfolio and Mako product technology.</li><li>Stryker had a strong performance from its more emergent businesses, which include its core trauma business, and Neurovascular gave another standout performance.</li></ul>

Stryker Corporation had a decent result in the quarter and the company posted an increase in organic sales growth which was driven by double-digit growth from its Neuro-technology and MedSurg businesses.Though the company’s implant businesses were challenged, the company’s capital products performed better than its MedSurg portfolio and Mako product technology.Stryker had a strong performance from its more emergent businesses, which include its core trauma business, and Neurovascular gave another standout performance.

Stryker Corporation: Business Strategy & Key Growth Drivers

Credit

<ul><li>Stryker Corporation’s Neurotechnology and MedSurg businesses were the major drivers of its solid organic growth in 2021.</li><li>Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.</li><li>The international organic sales have also shown a robust growth wedged by positive sales momentum in emerging markets.</li></ul>

Stryker Corporation’s Neurotechnology and MedSurg businesses were the major drivers of its solid organic growth in 2021.Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.The international organic sales have also shown a robust growth wedged by positive sales momentum in emerging markets.

Stryker Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report

<ul><li>Stryker Corp had a decent result with a good performance in terms of organic sales.</li><li>Though its implant business diminished, the company saw the robust result for its capital products and Mako product technology over its MedSurg portfolio.</li><li>Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.</li></ul>

Stryker Corp had a decent result with a good performance in terms of organic sales.Though its implant business diminished, the company saw the robust result for its capital products and Mako product technology over its MedSurg portfolio.Stryker had robust performances from its more emerging businesses, including a standout performance by Neurovascular and its core trauma business.

Stryker Corporation: Financial & Price Forecasts

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

MicroPort NeuroTech / Equity Capital Markets

<ul>
<li>Microport NeuroTech is a leading neuro-interventional device company in China. The company is looking to raise up to USD 300m via a Hong Kong listing.</li>
<li>We look at the company's key segments and products. We like the company's comprehensive coverage of neuro-interventional devices.</li>
<li>Its management team has decent experience as it is a spin-off from Microport. We also highlight the risk of the stock.</li>
</ul>


Microport NeuroTech is a leading neuro-interventional device company in China. The company is looking to raise up to USD 300m via a Hong Kong listing.
We look at the company's key segments and products. We like the company's comprehensive coverage of neuro-interventional devices.
Its management team has decent experience as it is a spin-off from Microport. We also highlight the risk of the stock.


Microport NeuroTech (微创脑科学) Pre-IPO: Decent Name for Neuro-Interventional Devices

<ul><li>Stryker’s performance has been negatively impacted by the new Covid-19 vaiant.</li><li>The company did manage to deliver decent results from its more emerging businesses, including its core trauma business and another exceptional performance from its neurovascular side.</li><li>Stryker’s organic growth rate for the year to date is around 7.6% which is relatively low.</li></ul>

Stryker’s performance has been negatively impacted by the new Covid-19 vaiant.The company did manage to deliver decent results from its more emerging businesses, including its core trauma business and another exceptional performance from its neurovascular side.Stryker’s organic growth rate for the year to date is around 7.6% which is relatively low.

United States

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products.  The Company's products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stryker Corp (SYK US)

Stryker Corporation: Business Strategy & Key Growth Drivers

Stryker Corporation had a decent result in the quarter and the company posted an increase in organic sales growth which was driven by double-digit...

Baptista Research

Stryker Corporation: Detailed Credit Analysis & Financial Strength Evaluation Report

Stryker Corporation’s Neurotechnology and MedSurg businesses were the major drivers of its solid organic growth in 2021. Stryker had robust...

Baptista Research

Stryker Corporation: Financial & Price Forecasts

Stryker Corp had a decent result with a good performance in terms of organic sales. Though its implant business diminished, the company saw the...

Baptista Research

Microport NeuroTech (微创脑科学) Pre-IPO: Decent Name for Neuro-Interventional Devices

Microport NeuroTech is a leading neuro-interventional device player in China with proven track record of R&D and commercialization. The company is...

Ke Yan, CFA, FRM

Stryker Corporation - Investment Thesis

Stryker’s performance has been negatively impacted by the new Covid-19 vaiant. The company did manage to deliver decent results from its more...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)